Oral NLRP3 inhibitors for inflammation
Pricing expected any day (our estimate) · latest SEC filing Nov 9, 2026.
Pinch-zoom for details.
Use of proceeds, per the filing: With existing cash, to take ruvonoflast through Phase 3 topline data in PAD, expected in 2028.
Rezera is a clinical-stage biotech developing oral drugs that block NLRP3, a driver of inflammation. Its lead drug, ruvonoflast, is headed into a Phase 3 trial in peripheral artery disease (PAD).
Fiscal year
1st half
Fiscal year
1st half
Cash and equivalents on the latest balance sheet, actual and as adjusted for the offering, as shown in the filing.
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Operating result | (23.4M) | (41.0M) | −75.2% | (13.9M) | (24.6M) | −76.3% |
| Net result | (25.2M) | (42.2M) | −67.3% | (13.7M) | (25.5M) | −86.1% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Operating result | (23.4M) | (41.0M) | −75.2% |
| Net result | (25.2M) | (42.2M) | −67.3% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Operating result | (13.9M) | (24.6M) | −76.3% |
| Net result | (13.7M) | (25.5M) | −86.1% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
In plain English, from the filing's risk factors.
In plain English, from the filing's strategy section.
Source: Rezera Inc.'s Form S-1/A, filed with the SEC on Nov 9, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back